.jpg)
Sonia Grego, CEO, and Sophie Chapelle, chief commercial officer, kicked off the year by attending the Crohn’s and Colitis Congress in Las Vegas. We held productive meetings with leading researchers interested in using Coprata’s Smart Sampling Toilet for studies in the fields of gut microbiome and IBD biomarkers.
Stool biomarkers (gut microbiome, inflammatory proteins, bile acids) hold promise for prediction of disease risk and response to therapy in chronic GI diseases, such as Crohn’s, Ulcerative Colitis, and many other conditions, including cancer and various infections.
While advances in molecular sequencing allow measurements of a larger number of biomarkers, such measurements are typically a snapshot in time and do not capture the rapid and dynamic changes of one’s physiology over time.
Research on fecal biomarkers with multiple timepoints would be ideal but is hampered by lack of access to stool specimens because of the general aversion to handle one’s stool for specimen collection. This challenge is particularly acute for study design with an equal number of diseased and healthy subjects.
Our Solution: Coprata provides unprecedented access to stool specimens via a smart toilet for the household. Our Smart Sampling Toilet enables hands-free specimen collection where stool is produced, with a complete absence of physical, visual or smell interactions, providing easily accessible time-dense specimen collection.
